- Published on
KembaraXtra- Medicine- Aphthous Ulcers
Aphthous ulcers are small, painful ulcers that occur predominantly on the oral mucosa. They are also known as aphthae, canker sores, recurrent oral aphthae, or recurrent aphthous stomatitis (RAS). The ICD-10CM code is K12.0 (Recurrent oral aphthae). The incidence is unknown, but prevalence is common—about one in five people experience them at some point in life. They most commonly affect women, adolescents, and adults under 40, with peak incidence in adolescence. Risk factors include genetic predisposition, stress, local trauma, tobacco exposure, viral or bacterial infections, nutritional deficiencies, and endocrine or autoimmune diseases. Genetics play a role, as up to 40% of patients report a family history.
Clinically, aphthous ulcers are typically small round or oval lesions with a gray-white or yellow pseudomembranous base and an erythematous (red) halo. They can occur at any age, often beginning in childhood and commonly improving by the third decade. The exact cause is not well understood and is likely multifactorial, with contributors such as trauma (biting, dental appliances/braces), nutritional deficiencies, infections, medications, food hypersensitivity, hormonal/endocrine changes, and tobacco use. When ulcers recur without an identified systemic disease, the condition is termed recurrent aphthous stomatitis (RAS).
RAS is divided into three subtypes. Minor RAS (about 80%) presents as 1 to 5 shallow ulcers that are <10 mm, usually on the lips, buccal mucosa, tongue, and floor of mouth, they typically resolve in 4 to 14 days without scarring. major ras (about 10%) features larger (>10 mm), deeper ulcers that may be more numerous and extend to areas like the gingiva and pharyngeal mucosa; they last weeks to months and have a higher risk of scarring. Herpetiform RAS (about 10%) consists of many very painful small ulcers (1–3 mm) occurring in large numbers (5 to 100), often involving the floor of mouth and ventral tongue; ulcers may cluster and coalesce into larger irregular lesions, generally resolving within 14 days and usually without visible scarring. Despite the name, herpetiform RAS is not caused by herpes.
The differential diagnosis is broad, especially when ulcers are severe, persistent, atypical, or associated with systemic findings. Important considerations include Behçet syndrome, MAGIC syndrome, systemic lupus erythematosus, gluten-sensitive enteropathy, inflammatory bowel disease, HIV infection, herpes simplex virus, cyclic neutropenia, PFAPA syndrome, hyperimmunoglobulin D syndrome, agranulocytosis, autoimmune bullous disease, oral erosive lichen planus, drug-induced mucosal ulcers, contact dermatitis, and squamous cell carcinoma. Differentiating HSV from aphthous ulcers is useful: HSV tends to involve keratinized tissue, often has a vesicle phase and prodrome, whereas aphthous ulcers usually occur on movable, nonkeratinized mucosa, lack vesicles, and have nonspecific biopsy findings if biopsied.
Workup begins with a detailed clinical history (associated symptoms, family history, frequency, number/size, duration, location, and presence of any nonoral lesions) and physical examination describing lesion appearance and distribution. RAS is usually a clinical diagnosis. Biopsy is typically not required, but it may be helpful in severe, persistent, or atypical cases to exclude other mucosal pathology or malignancy. If RAS is severe, persistent, or begins later in life, laboratory evaluation is reasonable to look for underlying contributors. Suggested labs include CBC, inflammatory markers (ESR, CRP), and nutritional studies such as vitamin B12, folate, and iron. Imaging studies are not indicated.
Treatment is primarily supportive and stepwise, because etiology is unclear and there is no curative medication. Good oral hygiene and avoidance of triggers (trauma, braces/hardware irritation, known food/drug triggers) are foundational. For symptomatic relief, topical anesthetics can be used, especially before meals, including 2% viscous lidocaine applied directly or “swish and spit,” and diphenhydramine liquid (12.5 mg/5 mL) using 5 mL swish and spit. Topical corticosteroids are first-line for mild to moderate RAS, such as dexamethasone elixir (0.5 mg/5 mL) with 5 mL swish and spit three to four times daily. In more severe cases or in immunosuppressed patients, topical antimicrobials may reduce secondary infection risk, including chlorhexidine 0.12% mouth rinse (15 mL swish and spit twice daily) and nystatin suspension (“swish and swallow” four times daily) when candidal overgrowth is a concern.
For patients who do not improve with topical therapy alone or who have severe disease, oral options may be used. Oral prednisone 20–40 mg daily for 4–7 days is the first-line treatment for acute severe RAS. Montelukast 10 mg daily may be considered as a safer alternative in severe RAS that is not well controlled with oral corticosteroids. Complementary options sometimes used as adjuncts include ascorbic acid 2000 mg/day (particularly for minor RAS) and zinc 50 mg/day to support wound healing. Nonpharmacologic adjuncts like laser therapy or chemical cauterization have been used to reduce acute pain, but overall efficacy is unclear.
Disposition is generally reassuring because aphthous ulcers and RAS are typically self-resolving, with average healing around 2 weeks, and prognosis is excellent. However, clinicians should consider alternative causes when ulcers are persistent, unusually severe, occur outside typical patterns, or are accompanied by systemic symptoms. Referral is recommended when another diagnosis is suspected; severe or persistent RAS may be referred to dermatology. Prevention focuses on good oral hygiene, trigger avoidance, and ensuring adequate nutrition, especially addressing deficiencies. Patient and family education should emphasize pain control (using topical anesthetics before eating/drinking to prevent dehydration and before oral hygiene), avoidance of irritating foods such as citrus, spicy, salty foods, and return precautions including worsening pain, spreading ulcers beyond oral mucocutaneous membranes, fever, decreased oral intake, or other systemic symptoms.
Aphthous ulcers are small, painful ulcers that occur predominantly on the oral mucosa. They are also known as aphthae, canker sores, recurrent oral aphthae, or recurrent aphthous stomatitis (RAS). The ICD-10CM code is K12.0 (Recurrent oral aphthae). The incidence is unknown, but prevalence is common—about one in five people experience them at some point in life. They most commonly affect women, adolescents, and adults under 40, with peak incidence in adolescence. Risk factors include genetic predisposition, stress, local trauma, tobacco exposure, viral or bacterial infections, nutritional deficiencies, and endocrine or autoimmune diseases. Genetics play a role, as up to 40% of patients report a family history.
Clinically, aphthous ulcers are typically small round or oval lesions with a gray-white or yellow pseudomembranous base and an erythematous (red) halo. They can occur at any age, often beginning in childhood and commonly improving by the third decade. The exact cause is not well understood and is likely multifactorial, with contributors such as trauma (biting, dental appliances/braces), nutritional deficiencies, infections, medications, food hypersensitivity, hormonal/endocrine changes, and tobacco use. When ulcers recur without an identified systemic disease, the condition is termed recurrent aphthous stomatitis (RAS).
RAS is divided into three subtypes. Minor RAS (about 80%) presents as 1 to 5 shallow ulcers that are <10 mm, usually on the lips, buccal mucosa, tongue, and floor of mouth, they typically resolve in 4 to 14 days without scarring. major ras (about 10%) features larger (>10 mm), deeper ulcers that may be more numerous and extend to areas like the gingiva and pharyngeal mucosa; they last weeks to months and have a higher risk of scarring. Herpetiform RAS (about 10%) consists of many very painful small ulcers (1–3 mm) occurring in large numbers (5 to 100), often involving the floor of mouth and ventral tongue; ulcers may cluster and coalesce into larger irregular lesions, generally resolving within 14 days and usually without visible scarring. Despite the name, herpetiform RAS is not caused by herpes.
The differential diagnosis is broad, especially when ulcers are severe, persistent, atypical, or associated with systemic findings. Important considerations include Behçet syndrome, MAGIC syndrome, systemic lupus erythematosus, gluten-sensitive enteropathy, inflammatory bowel disease, HIV infection, herpes simplex virus, cyclic neutropenia, PFAPA syndrome, hyperimmunoglobulin D syndrome, agranulocytosis, autoimmune bullous disease, oral erosive lichen planus, drug-induced mucosal ulcers, contact dermatitis, and squamous cell carcinoma. Differentiating HSV from aphthous ulcers is useful: HSV tends to involve keratinized tissue, often has a vesicle phase and prodrome, whereas aphthous ulcers usually occur on movable, nonkeratinized mucosa, lack vesicles, and have nonspecific biopsy findings if biopsied.
Workup begins with a detailed clinical history (associated symptoms, family history, frequency, number/size, duration, location, and presence of any nonoral lesions) and physical examination describing lesion appearance and distribution. RAS is usually a clinical diagnosis. Biopsy is typically not required, but it may be helpful in severe, persistent, or atypical cases to exclude other mucosal pathology or malignancy. If RAS is severe, persistent, or begins later in life, laboratory evaluation is reasonable to look for underlying contributors. Suggested labs include CBC, inflammatory markers (ESR, CRP), and nutritional studies such as vitamin B12, folate, and iron. Imaging studies are not indicated.
Treatment is primarily supportive and stepwise, because etiology is unclear and there is no curative medication. Good oral hygiene and avoidance of triggers (trauma, braces/hardware irritation, known food/drug triggers) are foundational. For symptomatic relief, topical anesthetics can be used, especially before meals, including 2% viscous lidocaine applied directly or “swish and spit,” and diphenhydramine liquid (12.5 mg/5 mL) using 5 mL swish and spit. Topical corticosteroids are first-line for mild to moderate RAS, such as dexamethasone elixir (0.5 mg/5 mL) with 5 mL swish and spit three to four times daily. In more severe cases or in immunosuppressed patients, topical antimicrobials may reduce secondary infection risk, including chlorhexidine 0.12% mouth rinse (15 mL swish and spit twice daily) and nystatin suspension (“swish and swallow” four times daily) when candidal overgrowth is a concern.
For patients who do not improve with topical therapy alone or who have severe disease, oral options may be used. Oral prednisone 20–40 mg daily for 4–7 days is the first-line treatment for acute severe RAS. Montelukast 10 mg daily may be considered as a safer alternative in severe RAS that is not well controlled with oral corticosteroids. Complementary options sometimes used as adjuncts include ascorbic acid 2000 mg/day (particularly for minor RAS) and zinc 50 mg/day to support wound healing. Nonpharmacologic adjuncts like laser therapy or chemical cauterization have been used to reduce acute pain, but overall efficacy is unclear.
Disposition is generally reassuring because aphthous ulcers and RAS are typically self-resolving, with average healing around 2 weeks, and prognosis is excellent. However, clinicians should consider alternative causes when ulcers are persistent, unusually severe, occur outside typical patterns, or are accompanied by systemic symptoms. Referral is recommended when another diagnosis is suspected; severe or persistent RAS may be referred to dermatology. Prevention focuses on good oral hygiene, trigger avoidance, and ensuring adequate nutrition, especially addressing deficiencies. Patient and family education should emphasize pain control (using topical anesthetics before eating/drinking to prevent dehydration and before oral hygiene), avoidance of irritating foods such as citrus, spicy, salty foods, and return precautions including worsening pain, spreading ulcers beyond oral mucocutaneous membranes, fever, decreased oral intake, or other systemic symptoms.
0 Comments
